Down 44%, Should You Buy the Dip on Viking Therapeutics?

Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s ...
Zacks Investment Research on MSN

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...
Stocktwits on MSN

Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside

Viking on Thursday reported a third-quarter loss per share of $0.81, compared to the expected loss of $0.7 per share. ・Morgan ...
Seeking Alpha

Viking prices secondary offering at $44.20

Viking (NYSE:VIK) priced its secondary offering of an aggregate of ~30.53M ordinary shares at a public offering price of $44.20 per share. The offering is expected to close on May 29, 2025. The ...
Nasdaq

Viking Announces Pricing Of Secondary Offering Of About 30.53 Mln Shares At $44.20/shr

(RTTNews) - Viking Holdings Ltd (VIK) announced the pricing of its secondary offering of an aggregate of about 30.53 million ordinary shares at a public offering price of $44.20 per share. The ...
Yahoo Finance

Down 44%, Should You Buy the Dip on Viking Therapeutics?

Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s approaching $100 billion. This biotech has candidates in phase 2 and phase ...